T he nonstructural Nef protein of HIV-1 is a critical contributor to viral pathogenicity in a variety of ways (1) (2) (3) (4) . Nef is a conglomerate of protein-protein interaction modules, intersecting multiple cellular trafficking, and signaling pathways (5, 6) . Nef affects the expression of a variety of molecules on the APC surface that are critical in the generation of immune responses. Notably Nef mediates the down-regulation of cell surface levels of both classes of MHC molecules, as well as cell surface levels of the immune costimulatory molecules CD80 and CD86 (7) (8) (9) .
Viruses that fuse at the plasma membrane and release most of their proteins directly into the cytosol, as well as viruses that establish persistent latent infections and constitutively express low levels of cytosolic Ags, have been found to be effectively detected by the presentation of cytosolic viral epitopes on MHC class II (MHCII) 4 (10) . Viruses use multiple strategies to circumvent MHCII-dependent immunity, a common one being alteration in the cellular trafficking of MHCII (11) . MHCII molecules extensively negotiate the endolysosomal system. Nascent MHCII molecules in complex with the invariant chain (Ii) exit the endoplasmic reticulum and move through the Golgi apparatus before intersecting the endocytic system in specialized MHCII peptide-loading compartments variously termed MIIC (MHCII-enriched compartment) or CIIV (class II vesicles) (12, 13) . These compartments are thought to be a collection of late endocytic or lysosomal compartments containing the necessary components for Ii degradation and efficient peptide loading on MHCII before its egress to the cell surface (13, 14) . Constitutive endocytosis and recycling of cell surface MHCII have also been well documented (15) and are considered a pathway for the presentation of some Ags (16) , although the molecular regulators of such trafficking are not yet well understood. The extensive dependence of MHCII on the endocytic system for its function offers a potential target for viral subversion. Nef has been reported to inhibit MHCII-dependent Ag presentation by the reduction of cell surface levels of mature MHCII and the up-regulation of immature MHCII, which are functionally incompetent because of persistent association with the Ii (9) . In the presence of Nef, mature MHCII molecules are reduced at the cell surface and are found at high levels in intracellular lysosomal compartments. The delivery of immature MHCII to the endolysosomal compartment is also impaired, resulting in reduced Ii degradation (17) . Mutational analysis suggests that these mechanisms are well conserved among nef alleles (18) .
Endocytic mechanisms involve a variety of internalization pathways with variable dependence on factors such as coat proteins like clathrin and caveolin, levels of membrane cholesterol, and scissoring agents such as dynamin (Dyn) and small GTPases of the Rho family (19, 20) . This potentially provides Nef with an assortment of molecular adaptors that can be subverted. Nef is known to affect many of these endocytic programs to modulate the expression of several cell surface molecules (4) .
On this background, we have examined the process by which Nef mediates the redistribution of MHCII in human monocytic cells. We find that Nef triggers MHCII internalization in a cholesterol-dependent but clathrin-and Dyn-independent manner that closely mimics the constitutive endocytosis of peptide-MHCII molecules. These findings indicate that Nef exploits a constitutive endocytic program to subvert surface MHCII expression in HIVinfected cells.
Materials and Methods

Plasmids and reagents
The F2-nef gene from an Indian HIV-1 subtype C primary isolate cloned into pIRES2-EGFP or pEGFP-N3 has been described earlier (7) . The K44A dominant negative (DN)-Dyn construct was obtained from Dr. M. McNiven (Mayo Clinic, Rochester, MN), the DN Eps15 construct from Dr. A. Dautry-Varsat (Institut Pasteur, Paris, France), the Rab11 constructs from Dr. N. Bunnett (University of California, San Francisco, CA), and the Rab5-and Rab7-related constructs from Dr. M. Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany) for use as described earlier (21) .
The following reagents were used: fluorophore-labeled dextran (tetramethylrhodamine-dextran) and transferrin (Tf) (Molecular Probes), mAbs against Rab5, Rab11, EEA1, LAMP1 (Transduction Laboratories), and Rab7 (Santa Cruz Biotechnology), anti-human MHCII (L243) either purified from culture supernatants or used as a biotin conjugate (Serotec), and purified anti-MHCII mAb labeled with either Cy5 (Amersham), or with Alexa Fluor dyes (Molecular Probes). The mAbs Y-Ae (anti-Ea 52-68 -H-2A b ) and Y3P (anti-H-2A b ) have been described previously (22) . Labeled secondary detection reagents used included goat anti-mouse IgG (Fc)-PE, donkey anti-rat IgG (Fc)-PE (Jackson ImmunoResearch Laboratories), streptavidin-PE, streptavidin-CyChrome, and streptavidin-PE-Texas Red (BD PharMingen).
Cells and transfection
BMC-2 cells were maintained in Click's medium with FCS, 2-ME, Lglutamine, and antibiotics. U937 cells were maintained in RPMI 1640 medium with FCS and antibiotics. Cells were kept in 0.5 g/ml LPS overnight before use to enhance MHC levels. Primary murine monocytes were grown from mouse bone marrow by culturing nonadherent mouse bone marrow cells with M-CSF (30% L929 fibroblast-conditioned medium as M-CSF source) for 7 days, with periodic growth factor replenishment. Primary human monocytes were grown from PBMC by culturing them with rM-CSF (100 U/ml; Sigma-Aldrich) for 3 days, and live cells were used for infection in the continuing presence of the growth factor. Transfections of cell lines and mouse primary cells were done using FuGENE 6 (Roche) or Effectene (Qiagen), according to the manufacturers' protocols. Primary human monocytes were transfected by nucleoporation according to the manufacturer's protocol (Amaxa). Briefly, 1 ϫ 10 6 cells were resuspended in Nucleofector solution followed by the addition of 4 -6 g of plasmid DNA and cells were nucleoporated following manufacturer's instructions (Amaxa).
Antigens
A recombinant fusion protein (GST-Ea 52-68 -Myc) consisting of GST, aa residues 52-68 of the mouse H-2Ea sequence (Ea 52-68 ), and the oligopeptide sequence of the c-Myc protein was made in Escherichia coli from the plasmid pGEX-2T as described previously (22) .
Immunofluorescence microscopy and image processing
Cells were fixed with 4% paraformaldehyde for 20 min at 37°C and permeabilized using 0.3% Tween 20 or 0.03% saponin in PBS for 20 min at ambient temperature. They were then blocked with 2 mg/ml BSA in PBS before incubation with Abs in the same medium. Rabbit and mouse primary Abs were detected using fluorophore-labeled, Fc-specific anti-rabbit IgG or anti-mouse IgG.
Confocal and wide field microscopy
Confocal imaging was conducted on a Zeiss LSM510 confocal microscope (Zeiss) equipped with factory set dichroics and an argon-krypton laser using the Zeiss software with a step size of 0.1 m and a digital zoom of 3.5 corresponding to a pixel size of 0.10 m was used. Pinhole size was kept constant at 272 U (optical section, Ͻ2 m; airy units, Ͻ3), and 12 bit images were collected at ϫ63 original magnification and a 1.45 numerical aperture (NA) objective.
Optimized dichroics, excitation, and emission filters were used as described (23) . Fluorophores were imaged for multiwavelength analysis using appropriate filter sets. For four-color imaging, either factory-set dichroics (Zeiss) or spectral separation by the 32-channel Meta detector (Zeiss) with dye-specific laser line excitation was used. The absence of crossexcitation was confirmed in both approaches (data not shown).
High-resolution, wide-field images were collected using Nikon TE 300 inverted microscope equipped with ϫ60 original magnification/1.4 NA objective and ϫ20 original magnification/0.75 nuclear NA, a mercury arc illuminator (Nikon), and a cooled charge-coupled device camera (Princeton Instruments) controlled by Metamorph software (Molecular Devices).
Quantitative colocalization analysis
Colocalization between internalized vesicles and endocytic markers was quantified using two types of software, MultiSpots and MultiColloc (21, 24) , variations of the custom-developed software, Spots and Coloc, respectively, as described previously (21, (25) (26) (27) (28) . The criteria outlined below were applied to images obtained from U937 cells labeled with Abs against Rab5, EEA1, Rab7, Rab11, and LAMP1 or pulsed with the endocytic tracers Tf and dextran for 10 min at 37°C. High-resolution images of cells labeled with endocytic tracers were obtained using a ϫ60 original magnification, 1.4 NA objective on a wide-field microscope at a pixel resolution of 0.15um/pixel. The images were corrected for background fluorescence using the "produce background correction" image procedure in Metamorph image analysis software with the following parameters suitable for producing a local background image while at the same time preserving the intensity of the endosomes (box size, 30 ϫ 30 pixels; subsample ratio, 10; percentile, 0.2).
The background corrected images were then processed through MultiSpots to identify endosomes using parameters defined by pixels above a threshold (set by inspection for each image) and area (minimum, 3 pixel; maximum, no upper limit). A trimming procedure was applied to isolate and segregate individual endosomes based on the inclusion of pixels with intensities Ͼ0.3 of maximal intensity within a unit of connected pixels having an intensity greater than that of the set threshold. This was achieved by an iterative procedure using a step size (0.01) for each iteration with limits for the number of iterations of the trimming procedure. The resultant image contains a set of identified "spots or endosomes" quantified in terms of net intensity per spot and total pixel area per spot.
The two "spotted" images of different fluorophore-labeled markers were matched up against each other to identify the endosomes wherein the two molecules were colocalized. Endosomes in a tracer image (e.g., MHCIIassociated endosomes) were compared with endosomes in a reference image (e.g., Rab11-containing endosomes) using MultiColoc, and endosomes with Ն50% area overlap were considered to be colocalized. The resultant image displayed all of the spots that were colocalized using a particular "tracer-reference" image pair.
Cell outlines were drawn based on the phase contrast image of the cell, and the net intensity of each fluorophore per cell was calculated in the spotted as well as the colocalized images using procedures in Metamorph. The percentage of colocalization was then calculated from the ratio of the net intensity within a cell in the MHCII with the appropriate Rab5/EEA1/ Rab11/etc-endocytic marker MultiColoc image to the net spot intensity of the same cell in the MHCII spots image. The maximum extent of colocalization obtained by this method is 90% for the colocalization of cointernalized Alexa Fluor 568-Tf and Alexa Fluor 647-Tf in the same cell. The percentage of colocalization is represented as a mean and SEM obtained from three independent experiments with a minimum of 50 cells per experiment. All images were processed for output purposes using Adobe Photoshop software. Digital color assignments were made for each fluorophore so as to provide maximum visual contrast.
Cell labeling and other treatments
U937 cells were transfected with various plasmids and surface labeled 12 h later with either biotinylated or primary-labeled anti-MHCII Ab on ice for 30 min. Cells were then warmed to 37°C and chased for varying lengths of time.
To visualize the endosomal distribution of the fluorescent tracers, the cell surface label (fluorophore-labeled Tf or anti-MHCII) was removed by using a combination of low pH and high pH buffers (ascorbate buffer (pH 4.5),160 mM sodium ascorbate, 40 mM ascorbic acid, 1 mM MgCl 2 , and 1 mM CaCl 2 ).
Flow cytometry
Cells were stained with primary and secondary reagents on ice for 30 min, as appropriate. For intracellular staining, cells were permeabilized with 0.03% saponin. Stained cells were analyzed on a BD-LSR flow cytometer (BD Biosciences) and data were analyzed using FlowJo software (Tree Star). All data shown are representative of 3-5 independent experiments.
Viruses and infection
HIV-1 viral stocks were generated by electroporation of HeLa cells with the infectious molecular clones pNL4-3 and pNL4-3 FS Nef (gifts from H. Gottlinger, University of Massachusetts Medical School, Worcester, MA) or pNL4-3 ADA and pNL4-3 ADA⌬Nef (gifts from M. Stevenson, University of Massachusetts Medical School, Worcester, MA). Virus stocks were harvested 72 h later and filter sterilized. U937 cells or primary human monocytes were serum starved for 1 h before infection. For each infection, 1 ϫ 10 6 cells were infected with 100,000 -200,000 cpm of reverse-transcriptase counts of virus. After 4 h of adsorption, cells were washed and incubated for 48 h before being stained for surface MHCII and intracellular p24 Gag protein.
Animals
C57BL/6 and bg/bg mice were obtained from The Jackson Laboratory and bred in the small animal facility of the National Institute of Immunology (New Delhi, India). All animal experiments were done under the approval of the Institutional Animal Ethics Committee.
Results
HIV-1 Nef reduces cell surface MHCII levels in myeloid cells
A wild-type (WT) nef gene (F2-nef) cloned from an Indian clinical isolate (7) was transfected into the human monocytic U937 cell line. Cell surface MHCII levels were reduced 5-to 10-fold at 48 h post-transfection (Fig. 1A ). This was accompanied by a reduction in the levels of MHC class I (MHCI), CD80, and CD86 as reported earlier (7), whereas levels of other molecules such as the Tf receptor did not exhibit any changes (Ref. 7 and data not shown). The total cellular levels of MHCII, however, as measured by staining postpermeabilization, were unaltered (Fig. 1A) . Furthermore, Nef expression led to a similar reduction of cell surface MHCII levels in the murine monocytic cell line BMC-2, although there was no reduction in the total cellular levels of MHCII postpermeabilization (Fig. 1A) . Similar effects were found on primary mouse bone marrow-derived dendritic cells and monocytes as well (data not shown). MHCII levels were also dramatically reduced on U937 monocytic cells infected with WT HIV-1, in contrast to cells infected with Nef-deficient HIV-1 (Fig. 1B) . The modest residual reduction in surface MHCII levels in the cells infected with Nefdeficient HIV-1 could be the effect of the Vpu protein of HIV-1, which has previously been shown to cause such a modest reduction in cell surface MHCII levels in monocytic cells (29) .
We next tested whether the reduction of cell surface MHCII levels observed in Nef-expressing U937 cells or in mouse monocytic cells was also observed in primary human monocytes. Human primary monocyte cultures were transfected to express enhanced GFP (eGFP) alone or Nef and eGFP. Expression of Nef in human primary monocytes also led to a reduction in cell surface MHCII levels (Fig. 1C) . We also confirmed that the infection of primary human monocytes with WT HIV-1 (Ada strain) led to substantial loss of cell surface MHCII levels, whereas infection with Nefdeleted HIV-1 (Ada) did so only modestly (Fig. 1D, right panel) . It is noteworthy that, under the conditions used, the two viruses did not show notable differences in their ability to infect primary human monocytes (Fig. 1D, left panel) . Thus, a reduction in cell surface MHCII levels by Nef is relevant for the human monocytic lineage.
To further characterize Nef-mediated down-modulation of MH-CII in monocytic cells, we tested some Nef mutants we have previously reported on for their effects on MHCI down-modulation in myeloid cells, using either the human cell line U937 and/or the mouse cell line BMC-2. All findings were consistent between the two cell lines. As expected, the GG to AA mutation of Nef at residues 2 and 3 (G2A), known to be deficient in myristoylation, was unable to down-regulate MHCI or MHCII (Table I) . Deletion mutants of Nef truncated from the C terminus to residue 130 continued to show efficient down-modulation of MHCI and MHCII, and while further deletion to residue 105 led to a loss of MHCI down-modulation, this mutant continued to down-modulate MHCII. However, a further deletion to residue 78 led to a loss of down-modulation of both MHCI and MHCII (Table I) . A clinical isolate of Nef mutated in both the WL57 site and the phosphofurin acidic cluster-sorting protein (PACS)-binding E4 site (D1-Nef) (7) also showed a loss of MHCI-and MHCII-down-modulation activity (Table I) .
Nef retards the delivery of MHCII molecules to the plasma membrane
Previous reports regarding the effects of Nef on cell surface MHCII levels could be interpreted to imply that Nef reduces the rate of MHCII delivery to the cell surface as well as accelerating the removal of cell surface MHCII molecules. We tested both of these possibilities. To test the effect of Nef on the delivery of intracellular MHCII to the cell surface, Nef-expressing U937 cells were stained 12 h after transfection with biotinylated anti-MHCII or anti-CD80 mAbs. They were then either held at 4°C or cultured at 37°C for 2 h. The cells were then stained with Cy3-streptavidin to detect the prelabeled molecules, as well as with the same anti-MHCII or anti-CD80 mAbs conjugated to PE to detect newly expressed molecules. Because the cell surface MHCII and CD80 were saturated with the first round of mAb binding, no staining was seen with the second round PElabeled mAbs when the cells had been held at 4°C, showing that no new MHCII or CD80 molecules had arrived at the surface (Fig. 1E) . However, if the cells were held at 37°C for 2 h, unlabeled CD80 appeared on the surface and the extent of expression of unlabeled CD80 was not different between eGFPexpressing or Nef-eGFP-expressing cells, indicating that Nef did not affect the rate of exocytosis of CD80 molecules to the cell membrane. In contrast, whereas newly delivered MHCII molecules could indeed be detected in cells held at 37°C, their levels were lower in Nef-expressing cells (Fig. 1E) , indicating that Nef retards the delivery of intracellular MHCII molecules to the cell surface.
Nef relocates cell surface MHCII to intracellular lysosomal compartments
Nef-mediated internalization of cell surface MHCII was next tracked by the disappearance of MHCII from the cell surface over time in eGFP-or Nef-expressing U937 cells, by labeling surface MHCII with biotinylated mAb and chasing for various times before flow cytometric estimation of surface label loss with fluorophore-labeled streptavidin. To confirm that the label lost from the surface was retained intracellularly, cells were also permeabilized and stained at each chase time point. The data show that in the absence of Nef, MHCII resides stably at the cell surface over an 8-h period, whereas in the presence of Nef MHCII was progressively lost from the surface but remained detectable intracellularly ( Fig. 2A) . We also tracked the internalization of cell surface MHCII molecules by labeling Nef-transfected U937 cells with fluorochrome-tagged 
a ϩ, Persistence of down-modulation ability; Ϫ, loss of down-modulation ability; (ϩ), weak persistence of down-modulation.
b MHCI-related data from Ref. 7. anti-MHCII Ab, followed by confocal microscopic examination over time. By 16 h after surface labeling, MHCII molecules had disappeared from the surface of Nef-expressing, but not from control eGFP-expressing U937 cells, and were relocated in intracellular compartments (Fig. 2B) .
To identify the intracellular compartment where MHCII was located in Nef-expressing cells, we examined Nef-eGFP-expressing U937 cells for colocalization of MHCII with markers of intracellular compartments by confocal microscopy. Nef-eGFP was colocalized with endogenous MHCII in intracellular organelles marked by the lysosomal marker LAMP-1 (Fig. 2C) . Although almost all cell surface MHCII was relocated under the influence of Nef into some LAMP-1-marked compartments, LAMP-1-marked compartments not containing MHCII could also be detected (Fig.  2C) , indicating that Nef induced MHCII relocation to specific vesicles within LAMP-1-marked regions.
Nef redistributes surface MHCII to the lysosomal compartment via endosomal vesicles
We next examined the colocalization of internalized MHCII in Nef-expressing cells with a range of vesicular and endosomal markers at intermediate stages of internalization to track the pathway of internalization (Fig. 2D) . Internalized MHCII molecules in Nef-expressing cells initially colocalized in vesicles bearing Rab5. If the cells were pulsed with either Tf or a fluid-phase marker, tetramethylrhodamine-dextran at appropriate times, initial colocalization was seen with both markers; but whereas Tf was rapidly sorted away from the MHCII, dextran showed stable colocalization. As MHCII-carrying endosomes lost Rab5, they moved into Rab7-bearing compartments from where they began to accumulate stably in LAMP-1-bearing vesicles. No colocalization was seen with either Arf6 or Rab11. These results suggest that, under the influence of Nef, MHCII traffics from early endosomal compartments to lysosomes along with fluid-phase cargo via late endosomal compartments, following the classical pathway of postendocytotic progression.
Molecular mediators of Nef-induced MHCII endocytosis
We next attempted to identify the molecular intermediates critical for Nef-mediated endocytosis of cell surface MHCII. Because Nef induces both an exocytic blockade and an enhanced endocytosis of MHCII, we distinguished between these two processes in many of the following experiments by using the methodology described above, namely labeling surface MHCII with biotinylated mAb and chasing for various times before flow cytometric estimation of surface label loss with fluorophore-labeled streptavidin. However, detection of cellular levels of MHCII without prior labeling also gave similar results in all instances.
Because MHCII molecules that are being internalized under the influence of Nef first enter compartments marked by the small GTPase Rab5, we examined whether Rab5 was involved in the process of removal. For this, U937 cells were cotransfected with Nef and either WT Rab5 or a DN mutant (S34N) (30) version of Rab5. Cells were stained 36 h later for cell surface MHCII or MHCI. In cells coexpressing Nef with DN Rab5, MHCII internalization was notably reduced whereas MHCI relocation was not blocked (Fig. 3A) . Similar data were obtained when cell surface MHCII molecules were prelabeled and chased. The removal of prelabeled MHCII from the surface of Nef-expressing U937 cells was retarded by DN Rab5, and was accelerated by a constitutively active (CA) (30) mutant (Q79L) of Rab5 (Fig. 3B) . These data thus implicated Rab5 in the Nef-mediated removal of cell surface MHCII and indicated a difference between the mechanisms of Nef-induced trafficking of cell surface MHCI and MHCII.
As shown above, Nef-mediated endocytosis of surface MHCII was followed by their delivery from early Rab5-bearing endosomes to late Rab7-bearing endosomes. A protein encoded by the lyst gene is known to modulate this trafficking. The beige mouse strain (Bg) harbors a mutation in the lyst gene and its cells show reduced sorting to late endosomal compartments (31) . Because Nef had similar effects on the removal of surface MHCI and MHCII in mouse myeloid cells (Ref. 7 and data above), we used bone marrow-derived monocytes (BMDMs) grown from either WT or Bg mice and transfected to achieve Nef expression. Nef-expressing Bg BMDMs showed reduced loss of surface MHCII although MHCI relocation was unaffected (Fig. 3C) , again indicating that Nef-mediated removal of MHCII was dependent on the endocytotic trafficking pathway from early to late endosomes.
We (24) and others (32) have previously reported that MHCI removal from the cell surface in Nef-expressing cells is dependent on cholesterol and phosphatidylinositol kinase (PIK) activity. We therefore tested whether MHCII removal in Nef-expressing cells was similarly controlled. Cellular cholesterol was depleted in U937 cells using the cholesterol-chelating agent methyl-␤-cyclodextrin (MBCD). MHCII removal from the cell surface was sensitive to MBCD (Fig. 4A) like MHCI removal (24) . Low concentrations of wortmannin (Wm), a PIK inhibitor reported to be specific for PI3K (33), did not affect Nef-mediated removal of MHCII whereas a higher concentration retarded it (Fig. 4B) , similar to the finding for MHCI removal (24) .
Although Nef-mediated CD4 internalization is Dyn dependent, that of MHCI, CD80, or CD86 is not (34) . We therefore tested the effect of the DN K44N mutant of Dyn-2 (DN Dyn) (35) or that of a short interfering RNA for Dyn-2 (sh-Dyn) (36) on Nef-mediated MHCII down-modulation in Nef-expressing U937 cells. DN Dyn had no effect on Nef-induced loss of cell surface MHCII (Fig. 4C) or MHCI, CD80, or CD86 as reported earlier (24), although Dyndependent Tf endocytosis was blocked as expected (Fig. 4C) . Similarly, sh-Dyn did not have any effect on the Nef-induced removal of cell surface MHCII (Fig. 4D) . DN versions of other GTPases known to be involved in many endocytotic pathways, such as Rho or Cdc42, did not have any effects on the removal of either MHCII or MHCI in Nef-expressing cells (data not shown). Furthermore, the blockade of molecular activities known to be crucial for the removal of the costimulatory molecules CD80 and CD86 from the surface of Nef-expressing myeloid cells, such as Rac, WASP, TIAM, Src, protein kinase C, or actin (24), had no effect on the reduction of surface MHCII levels in Nef-expressing cells (data not shown). To assess the role of clathrin in Nef-induced MHCII internalization, U937 cells were cotransfected with Nef and either a DN version of the clathrin adaptor protein Eps15 (95/295) (37) or a DN fragment of another adaptor protein, intersectin (intersectin-A) (38) . DN Eps-15 and intersectin-A blocked the uptake of Tf as expected (data not shown). In cells coexpressing Nef with DN Eps15 or intersectin-A, MHCII internalization was unaffected while MHCI relocation was blocked (Figs. 4, E and F) , identifying another difference between the Nef-induced trafficking pathways for MHCI and MHCII.
Together, these data indicate that although mechanisms for cell surface MHCI and MHCII removal in Nef-expressing cells have some similarities, they differ in their entry into Tf-and fluid phasemarked compartments and in their dependence on clathrin complexes vs Rab5 and Lyst activity.
We also confirmed that the role for Rab5 and the lack of a role for Eps15 in Nef-mediated relocation of MHCII was relevant in primary human monocytes as well. Human primary monocyte cultures were cotransfected to express Nef with either WT Rab5/DN Rab5 or WT Eps15/DN Eps15 as above and stained to assess surface MHCII levels. DN Rab5 blocked Nef-mediated relocation of MHCII whereas DN Eps15 did not (Fig. 4G) , confirming that the observations on U937 cells were consistent with those on primary human monocytes.
Cell surface MHCII was sorted to LAMP-1-bearing compartments via Rab7-bearing vesicles in Nef-expressing cells as shown above. The endocytosis of MHCII from the surface in Nef-expressing cells appears to be controlled by Rab5 and Lyst. We therefore examined whether Rab7 was crucial in mediating the Nef-mediated lysosomal delivery of MHCII. U937 cells were cotransfected with Nef and a DN mutant (N125I) version of Rab7. DN Rab7 did not block removal of cell surface MHCII (Fig. 5A) . However, although internalized MHCII was relocated to LAMP-1-bearing compartments in Nef-expressing cells carrying WT Rab7, this colocalization was blocked in DN Rab7-expressing cells (Figs. 5, B and C), demonstrating that Rab7 is critical for lysosomal delivery of internalized MHCII.
Endocytic intermediates involved in constitutive turnover of peptide-MHCII complexes
The data above indicated that Nef-mediated endocytotic removal of cell surface MHCII in both human and mouse myeloid cells was initiated by cholesterol-and PIK-dependent events requiring both Rab5 and Lyst. We next examined whether Nef assembled this de novo pathway for MHCII internalization or whether it subverted an existing pathway in the constitutive turnover of MHCII molecules. For this purpose, we generated specific peptide-MHCII (pMHCII) complexes on the surface of the mouse monocytic cell line BMC-2 and tracked its fate using a mAb specific for this pMHCII complex. A peptide from the endogenous protein H-2E-␣ (Ea52-68; Eap) binds with high affinity to the H-2A b MHCII molecule, and this pMHCII complex is specifically recognized by the Y-Ae mAb (39) . Therefore, cell surface pMHCII complexes were generated by pulsing BMC-2 cells with synthetic Eap for 60 min. Pulsed cells were incubated for varying times before being stained with either the pMHCII-specific mAb Y-Ae or the H-2A
b -specific mAb Y-3P for flow cytometry (Fig. 6A) or were labeled at 4°C with biotinylated Y-Ae or Y-3P and then incubated for varying times at 37°C followed by flow cytometric detection using fluorochrome-coupled streptavidin (Fig. 6B) . Y-Ae-binding pMHCII complexes generated on BMC-2 cells were lost rapidly from the cell surface, whereas the total H-2A b levels did not show any notable change (Figs. 6, A and B) . We then examined whether the molecular intermediates involved in Nef-mediated removal of cell surface MHCII also regulated the specific loss of Y-Ae-binding pMHCII complexes from the cell surface.
For this, BMC-2 cells were pulsed with Eap for 1 h at 37°C and labeled with biotinylated Y-Ae at 4°C as above, followed by incubation for varying times in the presence or absence of MBCD or Wm before the detection of levels remaining at the cell surface. The pMHCII complexes were lost more slowly from the surface if cholesterol was chelated (Fig. 6C) . Also, although a low Wm concentration did not affect the rate of removal of pMHCII complexes, a higher concentration, which has been reported to inhibit other PIKs in addition to PI3K (33) , also retarded the loss of surface pMHCII (Fig. 6D) .
To examine the role of Rab5, BMC-2 cells were transfected with constructs driving the expression of WT Rab5-eGFP, DN Rab5-eGFP, or CA Rab5-eGFP. Cells were pulsed 12 h posttransfection with Eap and labeled with Y-Ae as above and incubated for varying times before the detection of residual surface levels. The pMHCII complexes were lost more slowly from the surface of DN Rab5-expressing cells, while they were lost more rapidly in CA Rab5-expressing cells (Fig. 6E) .
We also examined the rate of loss of surface pMHCII complexes from WT and Bg cells. As described above, BMDMs grown from either WT or Bg mice were used. Cells were pulsed with Eap and labeled with Y-Ae as above and the loss of surface label was tracked. Bg BMDMs showed a slower loss of surface pMHCII complexes compared with WT cells (Fig. 6F) .
In similar assays, we also examined the effect of blocking molecular activities crucial for Nef-mediated removal of other cell surface molecules on the rate of pMHCII removal. Blocking the activities of WASP, Dyn, or Eps15 had no effect on the rate of loss of pMHCII complexes from the surface of BMC-2 cells (data not shown).
Together, these data indicate that short-lived pMHCII complexes on mouse monocytic cells, even in the absence of Nef, are removed from the cell surface by an endocytotic mechanism dependent on cholesterol, PIK, Rab5, and Lyst. This concordance between the trafficking pathways of total cell surface MHCII in Nef-expressing cells and those of specific pMHCII complexes in non-Nef-expressing cells suggests that Nef may be subverting constitutive pathways of MHCII endocytosis for the removal of cell surface MHCII molecules.
Discussion
In epithelial cells expressing the CIITA, Nef has been reported to affect MHCII-mediated Ag presentation by altering the intracellular trafficking of MHCII molecules to reduce the levels of mature MHCII and increase immature MHCII on the cell surface (9). Because Ii-associated immature MHCII is functionally incompetent, an immune evasion function has been suggested (9) . The delivery of immature MHCII to the lysosomes is also impaired, resulting in reduced Ii degradation (17) . However, in the presence of Nef, MH-CII is found at high levels in intracellular lysosomal compartments. Our results now extend these findings to professional APCs of the myeloid lineage and identify some molecular intermediates used by Nef to induce surface MHCII-down-regulation. We find that this pathway is similar to that used in constitutive endocytosis of peptide-MHCII complexes, indicating that Nef subverts a preexisting MHCII endocytic program.
Human as well as mouse myeloid cells are sensitive to these effects of Nef, and these observations are consistent between cell lines and primary monocytes of both human and mouse origin. The phenomenon is likely to be of some pathophysiological significance, because Nef-dependent loss of cell surface MHCII is seen on HIV-1 infection, although there are significant differences between the laboratory strain of HIV-1 and clinical isolates, raising the possibility of interesting variations in this property in the latter group. The loss of cell surface MHCII in monocytic cells expressing Nef is not accompanied by any loss of total cellular levels of MHCII, indicating that Nef mediates a cellular redistribution of MHCII. This characteristic is also seen with regard to MHCI, including our observation of a clinical isolate that is inefficient in the down-modulation of MHCI and MHCII, but not in that of CD80 and CD86.
The removal of cell surface MHCII could be the result of reduced delivery to the cell surface and/or enhanced removal by endocytosis. Unlike the case for MHCI, CD80, and CD86 (Ref. 7 and data not shown), MHCII delivery to the cell surface is retarded in Nef-expressing cells. However, Nef induces endocytic removal of all four of these target molecules. The eventual intracellular destinations of these molecules in Nef-expressing cells, are however, quite distinct. Although MHCI, CD80, and CD86 are removed to the Golgi region, MHCII relocates to the lysosomal compartment.
Similarly, the differences between the vesicular trafficking pathways followed by these target molecules in Nef-expressing cells are different and noteworthy. We observed recently that CD80 and CD86 are internalized into vesicles that do not show any markers of endosomal compartments and that they recruit Rab11 after a lag of some hours, using Rab11 activity for cargo delivery to the Golgi, although Rab11 activity is not required for the Golgi localization of MHCI (40) . In contrast, both MHCI (41) and MHCII enter early endosomal compartments marked by Rab5 and either fluid cargo and/or Tf. However, their pathways then diverge. MHCI molecules go on to the sorting compartment marked by Arf6 and then to the Golgi apparatus (41), whereas MHCII molecules move to the late endosomes marked by Rab7 and then to a LAMP-1-bearing lysosomal compartment using Rab7 activity.
Similarly, we find that the molecular intermediates involved in the Nef-mediated endocytosis of these four target molecules show major differences. CD80 and CD86 follow a unique endocytosis pathway defined by its dependence on protein kinase C, c-Src, TIAM, Rac, and actin and by being independent of cholesterol, clathrin, Dyn, and PIK activity (24) . In fact, we have not to date found any molecular intermediates shared by CD80/CD86 on the one hand and MHCI/MHCII on the other. However, MHCI and MHCII also show striking differences in the signaling intermediates used for their Nef-mediated endocytosis. Although both are cholesterol-and PIK-dependent and Dyn-independent, MHCI appears to use some form of the clathrin-adaptor complex whereas MHCII does not. Although both enter Rab5-containing vesicles, MHCI endocytosis does not depend on Rab5 or Lyst activity, whereas MHCII endocytosis does.
It is thus possible to argue for a model in which recycling MHCI enters sorting endosomes for a decision on whether they will be recycled back to the cell surface or not, which is where Nef may intervene and reroute them to the Golgi apparatus (41) . However, MHCII molecules may recycle through an early endosomal compartment dependent on the homologous fusion of early endosomes controlled by Rab5 so that the lack of Rab5 activity may lead to default delivery to late endosomes and then by normal endolysosomal Rab7-dependent maturation mechanisms to the lysosomes. Because Bg cells show defective trafficking to the late endosomal compartments and increased ability of these lysosomes to fuse with the plasma membrane (42, 43) , the loss of Nef-mediated MHCII down-regulation in Bg cells can perhaps be explained either by enhanced recycling back to the cell surface from early endosomes and/or by fusion of Bg lysosomes with the plasma membrane.
Such organized and branching cascades of signaled traffic suggests that Nef may be using pre-existing pathways normally used for the control of trafficking and turnover for these molecules. It is also of interest in this connection to note that, although Nef does bind to the cytosolic tails of CD80 and CD86 directly, evidence regarding its recruitment to the cytoplasmic portions of either MHCI or MHCII is sparse (9, 44), suggesting a possible alteration of normal turnover pathways rather than a directly induced endocytosis. We examined this possibility by testing whether peptide-MHCII complexes on the cell were normally internalized and, if so, whether the signaling intermediates needed for Nef-dependent removal of cell surface MHCII were also involved in the normal removal of pMHCII complexes. Our data indicate that pMHCII complexes are short lived on the cell surface and that their loss is indeed significantly dependent on cholesterol, PIK, Rab5, and Lyst activity.
There is thus a considerable degree of overlap between the molecular intermediates that are involved in the removal of YAe-reactive pMHCII complexes from the APC surface and those involved in the Nef-induced internalization of MHCII molecules. Both endocytic programs are sensitive to cholesterol depletion, require PIK activity, are dependent on Lyst as well as Rab5 function, and intracellular trafficking of the internalized complexes is Rab7 dependent. Thus, Nef appears to subvert a constitutive endocytic program that removes pMHCII complexes from the cell surface to mediate the removal of all MHCII molecules from the cell surface. How does Nef mediate the accelerated removal of MHCII molecules by such a constitutive pathway? In this context, an interesting difference between Nef-mediated MHCII removal and constitutive removal of pMHCII complexes is notable. The constitutive program appears to remove specific pMHCII complexes rapidly from the cell surface over time without affecting the equilibrium MHCII levels, whereas Nef extends this short-lived property to all cell surface MHCII molecules. Nef clearly retards the exocytosis of newly formed MHCII molecules, including their delivery to the endolysosomal compartments (17) , and we have observed in preliminary experiments that that inhibition of protein synthesis in normal APCs leads to a rapid loss of pre-existing cell surface MHCII molecules (data not shown). It is thus possible to visualize an intriguingly novel model in which the recycling of MHCII from endosomal compartments is dependent on the availability of new peptide as well as MHCII in those compartments, and their lack leads to a sorting decision in favor of lysosomal delivery. Further studies will be needed to establish the validity and mechanisms of such a process.
